The Application Of ATP-TCA Assay In Intravesical Chemotherapy For Non-muscle-invasive Bladder Cancer

Objective:To evaluate the feasibility of ATP-TCA?adenosine triphosphate tumor chemosensitivity assay?for the guide of drug slection in patients who received intravesical chemotherapy to prevent the recurrence of NMIBC?non-muscle-invasive bladder cancer?after operation.Methods:Twenty-four patients of non-muscle-invasive bladder cancer were selected from patients who had treatment in department of The first affiliated hospital of Wannan medical college in the period of years from June 2016 and December 2017.The fresh sterilized bladder superficial transient cell carcinoma specimens were purified and then primary tumor cell were cultured.And all of patients were selected to test by ATP-TCA,and giving individualized treatment according to the drug sensitivity.The control group was selected the drug by the expression of the doctors.The progression of disease was follow up.And the results of sensitivity and tolerance rates were dealt with statistically.Results:?1?.The sensitivity proportions of the 24 tumors for THP,MMC,EPI and GEM were 66.6%,16.7%,8.3%and 4.2%.The difference had statistical significance?pab=0.000;pac=0.000;pad=0.001?.?In 200%TDC?Test drug concentration?,The average inhibition ratio of the tumor growth for THP,MMC,EPI and GEM were 87.56,71.41,68.44 and 62.74.The difference had statistical significance(p^ab=0.013;p^ac=0.006;p^ad=0.000;p^bc=0.690;p^bd=0.177;p^cd=0.396).And in other Test drug concentration,we get the same results.?The recurrence rate of ATP-TCA group and the control group were 4.2%?1/24?and 33.3%?8/24?respectively,the recurrence rate have significance difference?p=0.033?.Conclusion:ATP-TCA assay for drug sensitivity test in vitro might provided experimental basis for clinical individual chemotherapy of non-muscle-invasive bladder cancer.Moreover,individualized treatment after test with ATP-TCA can reduce the recurrence rate of non-muscle-invasive bladder cancer.